Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT followed by camrelizumab and capecitabine for locally advanced pancreatic cancer
ChiCTR2300069272Phase 4Recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Mar 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab and capecitabine in pancreatic cancer (PC), sponsored by Sir Run-Run Shaw Hospital. Primary endpoint: Incidence of treatment-related adverse events and laboratory abnormalities. Started Mar 2023; status: recruiting.
02
Drugs
camrelizumabcapecitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2300069272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069272.